SEOUL: South Korea plans to mass-produce an antibody therapy of the novel coronavirus later this month, health authorities stated Tuesday.
The nation’s drug ministry is presently reviewing part 2/three medical assessments for the antibody-based therapy and goals to mass-produce business antibodies for the novel coronavirus in September, based on Kwon Jun-wook, deputy chief on the Central Disease Control Headquarters.
Health researchers are presently analysing outcomes of the part 1 trial, which was authorized by the drug ministry on July 17.
They additionally earned approval for the part 1 examine of the therapy in Britain on July 29.
For blood plasma-based therapy, health authorities stated the drug ministry authorized the part 2 examine of its growth on August 20, and 6 medical establishments, together with Samsung Medical Centre and Asan Medical Centre, will confirm its effectiveness and security on COVID-19 sufferers.
Health authorities added the blood plasma materials for the part 2 trial will start being produced Tuesday and provide of the substance shall be accomplished in mid-October.